Items where Subject is "R Medicine > RS Pharmacy and materia medica > RS400 Pharmaceutical chemistry > RS43.A64 Antineoplastic agents"

Group by: Creators | Item Type | Date | No Grouping

Number of items at this level: 3.

Patterson, L. H., McKeown, S. R., Robson, T., Gallagher, R., Raleigh, S. M. and Orr, S. (1999) Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anti-Cancer Drug Design. 14(6), pp. 473-486. 0266-9536.
Raleigh, S. M., Wanogho, E., Burke, M. D., McKeown, S. R. and Patterson, L. H. (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. International Journal of Radiation Oncology, Biology, Physics. 42(4), pp. 763-767. 0360-3016.
Raleigh, S. M., Wanogho, E., Burke, M. D. and Patterson, L. H. (1999) Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica. 29(11), pp. 1115-1122. 0049-8254.

This list was generated from NECTAR on Fri Nov 22 07:06:20 2024 GMT.

Export as	Atom RSS 1.0 RSS 2.0